poisar

Stocks · News reference

Bernstein Downgrades Summit Therapeutics to Underperform

Fiscal.ai

Bernstein has downgraded Summit Therapeutics from 'Market Perform' to 'Underperform' with a price target of $8.30.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. The Motley FoolTmf Breakfast News

    Breakfast News: Summit’s FDA Setback Isn’t the End

    Summit Therapeutics' shares plunged over 20% after receiving an FDA Complete Response Letter for its cancer drug ivonescimab, failing to meet overall survival statistical requirements in the HARMONi trial. However, analysts view the setback as limited since it affects only second-line treatment, with the drug's main blockbuster potential in first-line settings. Summit has 17 ongoing late-stage trials, strong financial backing from AstraZeneca, and $630 million in cash reserves to continue development.